Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Takeda Pharmaceutical Co (TKPHF), Omada Health, Inc. (OMDA)

Tipranks - Tipranks - Thu Apr 9, 3:48PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Takeda Pharmaceutical Co (TKPHF) and Omada Health, Inc. (OMDA) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Takeda Pharmaceutical Co (TKPHF)

In a report released today, Miki Sogi from Bernstein upgraded Takeda Pharmaceutical Co to Buy, with a price target of Yen6900.00. The company’s shares closed last Friday at $34.52.

According to TipRanks.com, Sogi is a 1-star analyst with an average return of -0.9% and a 43.8% success rate. Sogi covers the Healthcare sector, focusing on stocks such as Chugai Pharmaceutical Co, Daiichi Sankyo Company, and Astellas Pharma. ;'>

Currently, the analyst consensus on Takeda Pharmaceutical Co is a Moderate Buy with an average price target of $35.69, representing a 3.4% upside. In a report issued on March 26, TipRanks – xAI also upgraded the stock to Buy with a Yen6402.00 price target.

See the top stocks recommended by analysts >>

Omada Health, Inc. (OMDA)

In a report released today, David Roman from Goldman Sachs maintained a Buy rating on Omada Health, Inc., with a price target of $23.00. The company’s shares closed last Wednesday at $12.53, close to its 52-week low of $10.28.

According to TipRanks.com, Roman is a 1-star analyst with an average return of -4.9% and a 37.6% success rate. Roman covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Shoulder Innovations, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omada Health, Inc. with a $22.22 average price target, which is a 70.9% upside from current levels. In a report issued on March 29, TipRanks – PerPlexity also upgraded the stock to Buy with a $13.50 price target.

Read More on TKPHF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).